Clinical trials: Hospitalized COVID-19
Mild-to-moderate COVID-19
A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19
This randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of COVID-19 illness and the safety of KB109, a novel glycan, plus SSC versus SSC alone and measures of…
- Trial name
- NCT04414124
- Testing
- KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
- Where
- 16 sites in United States
- Volunteers
- 350 people
- Sponsor
- Kaleido Biosciences
COVID-19
Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
This study will measure the effect of FSD201 (ultramicronized PEA) + SoC vs placebo + SoC on Day 28, on disease progression in the confirmed coronavirus disease 2019 (COVID-19) patient population.
- Trial name
- NCT04619706
- Testing
- FSD201, Standard of Care for Covid-19
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Quantum Biopharma
COVID-19 Pulmonary Complications, COVID-19
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019…
- Trial name
- NCT04382586
- Testing
- Zanubrutinib, Supportive Care
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- BeiGene
Covid19
KAND567 Versus Placebo in Subjects Hospitalized With COVID-19
The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19 subjects in need of oxygen treatment.
- Trial name
- NCT06012565
- Testing
- KAND567, Microcrystalline cellulose
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 35 people
- Sponsor
- Novakand Pharma AB
Severe Pneumonia
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Phase 2 Study Objectives: efficacy and safety of of Reparixin treatment as compared to the control arm in adult patients with severe COVID-19 pneumonia Phase 3 Study Objectives: efficacy and safety of Reparixin treatment as…
- Trial name
- NCT04794803
- Testing
- Reparixin, Standard of care
- Where
- 4 sites in Brazil, Italy
- Volunteers
- 56 people
- Sponsor
- Dompé Farmaceutici S.p.A
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
COVID-19
A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients
This is a randomized study to assess safety, pharmacokinetics, immunogenicity, and efficacy of BAT2020 in hospitalized patients infected with COVID-19.
- Trial name
- NCT04432766
- Testing
- BAT2020
- Where
- United States
- Sponsor
- Bio-Thera Solutions
Covid19
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital…
- Trial name
- COROMEC (NCT04678193)
- Testing
- Coromec Registry with ECL-19
- Where
- 3 sites in United States, India and 1 more
- Volunteers
- 27,000 people, healthy volunteers welcome
- Sponsor
- Aventyn, Inc.
COVID-19, Coronavirus Infection
Study to Evaluate the Effect of a Probiotic in COVID-19
A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients…
- Trial name
- NCT04390477
- Testing
- Probiotic
- Where
- 2 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Bioithas SL
COVID-19
A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia
Evaluate the safety and effect of ORTD-1 on COVID-19 related pneumonia.
- Trial name
- NCT04708236
- Testing
- ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose
- Where
- United States
- Sponsor
- Oryn Therapeutics, LLC
COVID-19
A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients…
- Trial name
- NCT04628143
- Testing
- Nafamostat Mesilate
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Chong Kun Dang Pharmaceutical
COVID-19
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized…
- Trial name
- NCT04464395
- Testing
- CPI-006, Standard of Care
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
COVID-19
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19.
- Trial name
- COMMUNITY (NCT04590586)
- Testing
- Standard of care, Apremilast, Lanadelumab
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 515 people
- Sponsor
- Amgen
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy.
- Conditions
- Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral
- Trial name
- NCT05123755
- Testing
- AV-001 Injection
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vasomune Therapeutics, Inc.
Infections, Coronavirus
Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19
The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections and topical application, 12 mg in hospitalized patients with coronavirus disease (COVID-19).
- Trial name
- NCT04542226
- Testing
- Polyoxidonium
- Where
- 5 sites in Belarus, Russia
- Volunteers
- 81 people
- Sponsor
- NPO Petrovax
COVID-19
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
The study purpose was to assess the outcomes of therapy with olokizumab within complex therapy of Coronavirus disease 2019 (COVID-19) in hospitalised patients in real clinical practice setting.
- Trial name
- ROCOVI (NCT05196477)
- Testing
- Olokizumab, Standard therapy
- Where
- 6 sites in Russia
- Volunteers
- 3,087 people
- Sponsor
- R-Pharm
Covid-19
Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19
Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19
- Trial name
- NCT04454398
- Testing
- COVI-GUARD, Standard of Care
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19
This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19…
- Trial name
- CRISIS (NCT04425252)
- Testing
- Brequinar, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19.
- Trial name
- NCT04411628
- Testing
- LY3819253
- Where
- 11 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company